Sophia Antipolis, France
  • A €11M order backlog as of December 31, 2014 representing an increase of +134% as compared to 2013,
  • New projects awarded* for the interpretation and management of medical images for two phase III studies for non-small cell lung cancer, a phase II study for breast cancer, a phase I/II study for colorectal cancer and a phase I study for solid tumor cancers.

MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, announced today a €11M backlog as of December 31, 2014 (vs €4,7M as of December 31, 2013). MEDIAN Technologies has been selected to provide imaging solutions and services for five new clinical studies in oncology for a total amount of approximately €3.24M:

  • A phase III study (non-small cell lung cancer) for a total of €1.2M
  • A phase III study (non-small cell lung cancer) for a total of €731K
  • A phase II study (breast cancer) for a total of €408K
  • A phase I/II study (colorectal cancer) for a total of €307K
  • A phase I study (solid tumors) for a total of €593K.

“We are particularly proud that we have been awarded these new projects. These awards are a concrete illustration of MEDIAN’s capacity to penetrate new client accounts and also to generate repeat business through renewed confidence from existing clients”, said Jerome Windsor, VP Business Development Pharma. “These trials are sponsored by internationally known biotechnology companies and major pharmaceutical companies, one of which is predominant in Asia”.

“For the period September to December 2014 we have been awarded projects for a value of €7.2M” underlined Fredrik Brag, CEO of MEDIAN. “Together with our €11M order backlog at the end of the fiscal year it demonstrates our business model efficiency,” he added.

* A project award is a notification announcing that the company’s solution has been chosen for a specific project. This should result in a firm contract within 18 months, subject to the confirmation of clinical results upstream.

Download Microsoft-Word-20150212_PR_Backlog_EN.pdf